This inventor holds 4 USPTO granted patents and 3 EPO patents. Top assignee: Nippon Zoki Pharmaceutical Co., Ltd.. Active years: 2013-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013-2020
Title: Taizo Ito: Innovator in Pharmaceutical Chemistry
Introduction
Taizo Ito is a prominent inventor based in Kato, Japan. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 4 patents. His work focuses on developing novel compounds that have potential therapeutic applications.
Latest Patents
One of Taizo Ito's latest patents is a process for producing novel 4-benzoazonine derivatives. The objective of this invention is to provide a novel tetrahydroazepine compound and a method for its production. This invention relates to a tetrahydroazepine compound represented by a specific formula and includes a process for producing the compound or its salt. Another notable patent is for an aminopropylidene derivative, which exhibits excellent histamine receptor antagonistic action. This compound is particularly useful as a pharmaceutical composition, especially as an active ingredient that alleviates side effects in the central nervous system.
Career Highlights
Taizo Ito is associated with Nippon Zoki Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development in pharmaceutical innovations. His expertise in creating compounds with therapeutic potential has positioned him as a valuable asset in the industry.
Collaborations
Throughout his career, Taizo Ito has collaborated with notable colleagues, including Kunihiko Higashiura and Takashi Ogino. These collaborations have further enhanced his research capabilities and contributed to the success of his projects.
Conclusion
Taizo Ito's innovative work in pharmaceutical chemistry continues to impact the field significantly. His patents reflect his commitment to developing new therapeutic compounds that can improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile